Compare Neurocrine Biosciences Inc (NBIX) vs Western Digital Corp (WDC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Western Digital Corp — how do they compare? Neurocrine Biosciences Inc trades at $142.19 (market cap $14.36B), while Western Digital Corp trades at $388.9 (market cap $147.23B). The key difference: Western Digital Corp is far larger — about 10.3× Neurocrine Biosciences Inc's market cap, and Western Digital Corp pays a 0.15% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Western Digital Corp for 37 Days on average.
| NBIX | WDC | |
|---|---|---|
Market Cap | $14.36B | $147.23B |
Volume | 1,237,180 | 9,341,468 |
Sector | Health | Technology |
52-Week High | $185.50 | $746.23 |
52-Week Low | $123.10 | $113.13 |
Typical Hold Time | 23 Days | 37 Days |
Enterprise Value | $14.37B | $146.70B |
Dividend Yield | — | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Western Digital (WDC) trades at $405.21, down 1.42% amid recent sector volatility. The stock shows strong fundamentals with a P/E of 14.61 and impressive profitability metrics including 71.97% net income margin and 131.02% ROE. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $3.56 surpassing the $3.31 estimate. Technical indicators show bearish momentum with the price near key support at $400, while RSI at 29.60 suggests potential oversold conditions.
Despite near-term competitive pressures from Toshiba's production expansion, WDC maintains strong analyst support with 72% buy ratings and a $647.58 consensus target. The company's dominant 40%+ market share in HDDs and AI-driven storage demand provide long-term growth catalysts, though investors should monitor pricing pressure risks in the evolving AI storage landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →
